Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus

References

• Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019;25(11):1307–1326. doi:10.3748/wjg.v25.i11.1307
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147
   PubMed Web of Science ®Google Scholar
• Lomonaco R, Bril F, Portillo-Sanchez P, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care. 2016;39(4):632–638. doi:10.2337/dc15-1876
   PubMed Web of Science ®Google Scholar
• Li L, Yang X. The essential element manganese, oxidative stress, and metabolic diseases: links and interactions. Oxid Med Cell Longev. 2018;2018:7580707. doi:10.1155/2018/7580707
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:10.1016/S0016-5085(98)70599-2
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. doi:10.1002/hep.24001
   PubMed Web of Science ®Google Scholar
• Hu J, Yu Y. The function of thioredoxin-binding protein-2 (TBP-2) in different diseases. Oxid Med Cell Longev. 2018;2018:4582130. doi:10.1155/2018/4582130
   Web of Science ®Google Scholar
• Alhawiti NM, Al Mahri S, Aziz MA, Malik SS, Mohammad S. TXNIP in metabolic regulation: physiological role and therapeutic outlook. Curr Drug Targets. 2017;18(9):1095–1103. doi:10.2174/1389450118666170130145514
   PubMed Web of Science ®Google Scholar
• Ferreira NE, Omae S, Pereira A, et al. Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis. 2012;221(1):131–136. doi:10.1016/j.atherosclerosis.2011.12.009
   Web of Science ®Google Scholar
• Szpigel A, Hainault I, Carlier A, et al. Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes. Diabetologia. 2018;61(2):399–412. doi:10.1007/s00125-017-4462-5
   PubMed Web of Science ®Google Scholar
• Anderson EJ. Cutting calories and TXNIP from the skeletal muscle to restore insulin sensitivity. Diabetes. 2016;65(1):16–18. doi:10.2337/dbi15-0021
   Web of Science ®Google Scholar
• Gao Y, Chen S, Peng M, et al. Correlation between thioredoxin-interacting protein and nerve conduction velocity in patients with type 2 diabetes mellitus. Front Neurol. 2020;11:733. doi:10.3389/fneur.2020.00733
   Web of Science ®Google Scholar
• Xu LL, Gao W, Chen ZM, et al. Relationships between diabetic nephropathy and insulin resistance, inflammation, Trx, Txnip, CysC and serum complement levels. Eur Rev Med Pharmacol Sci. 2020;24(22):11700–11706. doi:10.26355/eurrev_202011_23815
   PubMed Web of Science ®Google Scholar
• Park HS, Song JW, Park JH, et al. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy. 2020;17:1–16.
   Web of Science ®Google Scholar
• Zhang X, Zhang JH, Chen XY, et al. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxid Redox Signal. 2015;22(10):848–870. doi:10.1089/ars.2014.5868
   PubMed Web of Science ®Google Scholar
• Mohamed IN, Sarhan NR, Eladl MA, El-Remessy AB, El-Sherbiny M. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: histological and immunohistochemical study. Acta Histochem. 2018;120(3):242–254. doi:10.1016/j.acthis.2018.02.006
   Web of Science ®Google Scholar
• Tang A, Desai A, Hamilton G, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416–425. doi:10.1148/radiol.14140754
   Web of Science ®Google Scholar
• Caussy C, Brissot J, Singh S, et al. Prospective, same-day, direct comparison of CAP with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging proton density fat fraction as the standard. Clin Gastroenterol Hepatol. 2020;18(8):1842–1850.e6. doi:10.1016/j.cgh.2019.11.060
   Web of Science ®Google Scholar
• Pinyopornpanish K, Leerapun A, Chattipakorn N, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021;15(6):827–840. doi:10.5009/gnl20367
   PubMed Web of Science ®Google Scholar
• Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020;170:108487. doi:10.1016/j.diabres.2020.108487
   PubMed Web of Science ®Google Scholar
• Kawamoto E, Tamakoshi K, Ra SG, Masuda H, Kawanaka K. Immobilization rapidly induces thioredoxin-interacting protein gene expression together with insulin resistance in rat skeletal muscle. J Appl Physiol. 2018;125(2):596–604. doi:10.1152/japplphysiol.00951.2017
   Web of Science ®Google Scholar
• Ahn B, Soundarapandian MM, Sessions H, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016;126(9):3567–3579. doi:10.1172/JCI87382
   Web of Science ®Google Scholar
• Zhou F, Zhang Y, Chen J, Hu Y, Xu Y. Verapamil ameliorates hepatic metaflammation by inhibiting thioredoxin-interacting protein/NLRP3 pathways. Front Endocrinol (Lausanne). 2018;9:640. doi:10.3389/fendo.2018.00640
   Web of Science ®Google Scholar
• Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15(6):607. doi:10.1007/s11892-015-0607-4
   PubMed Web of Science ®Google Scholar
• Kramer H, Pickhardt PJ, Kliewer MA, et al. Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy. AJR Am J Roentgenol. 2017;208(1):92–100. doi:10.2214/AJR.16.16565
   Web of Science ®Google Scholar
• Hu F, Yang R, Huang Z, et al. 3D Multi-Echo Dixon technique for simultaneous assessment of liver steatosis and iron overload in patients with chronic liver diseases: a feasibility study. Quant Imaging Med Surg. 2019;9(6):1014–1024. doi:10.21037/qims.2019.05.20
   Web of Science ®Google Scholar